Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC 1:50-200,ELISA 1:10000-20000,IF 1:50-200
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Expiry Date
12 months
Target
FASL
(Fas Ligand (TNF Superfamily, Member 6) (FASL))
Alternative Name
FAS-L
Background
Tumor necrosis factor ligand superfamily member 6, Apoptosis antigen ligand, APTL, CD95 ligand, CD95-L, Fas antigen ligand, Fas ligand, FasL, CD antigen CD178FASLG is a member of the tumor necrosis factor superfamily. The primary function of the encoded transmembrane protein is the induction of apoptosis triggered by binding to FAS. The FAS/FASLG signaling pathway is essential for immune system regulation, including activation-induced cell death (AICD) of T cells and cytotoxic T lymphocyte induced cell death. It has also been implicated in the progression of several cancers. Defects in FASLG may be related to some cases of systemic lupus erythematosus (SLE). Alternatively spliced transcript variants have been described. FASLG (Fas Ligand) is a Protein Coding gene. Diseases associated with FASLG include Autoimmune Lymphoproliferative Syndrome and Faslg-Related Autoimmune Lymphoproliferative Syndrome. Among its related pathways are Allograft rejection and Akt Signaling.